Indications and Management of Prednisolone Therapy

Absolute Indications for Starting Prednisolone

The American Association for the Study of Liver Diseases recommends starting prednisolone when serum aminotransferases exceed 10-fold the upper limit of normal, or when serum aminotransferases are 5-fold elevated with gamma-globulin at least 2-fold elevated, or when histology shows bridging/multilobular necrosis, as these are absolute indications for immunosuppressive therapy in autoimmune hepatitis 1, 2
Patients with severe disease, characterized by serum aminotransferases >10-fold upper limit of normal, have a high mortality risk without treatment, and untreated 10-year survival may be significantly compromised 1
Histological evidence of bridging necrosis or multilobular necrosis is an absolute indication for starting prednisolone, as it represents severe disease with high mortality risk without treatment 1, 2

Asymptomatic patients with mild disease may benefit from treatment, but this must be balanced against steroid-related risks, and the American Association for the Study of Liver Diseases suggests that untreated asymptomatic patients with mild disease have lower 10-year survival compared to treated patients (67% versus 98%, P < 0.01) 1
The American Association for the Study of Liver Diseases recommends that young individuals who tolerate medication well should be treated with corticosteroid therapy even for mild disease, as spontaneous improvement occurs in only 12% of untreated patients versus 63% in treated patients (P < 0.006) 1

The European Crohn’s and Colitis Organisation recommends prednisolone 40 mg daily for mild-to-moderate inflammatory bowel disease when prompt response is required or when mesalazine has failed 3
The American Gastroenterological Association suggests that steroid dependency or steroid excess indicates the need for alternative immunosuppression, and prolonged steroid use (>3 months continuous) carries increased mortality risk and should be avoided 4
The European League Against Rheumatism recommends high-dose systemic glucocorticoids (1-2 mg/kg/day, median 70 mg/day) as first-line treatment for severe myositis, especially with dyspnea, bulbar symptoms, severe weakness, or myocarditis 5, 6, 7

The American Association for the Study of Liver Diseases recommends two equally effective regimens for severe autoimmune hepatitis in adults: combination therapy with prednisolone and azathioprine, or monotherapy with prednisolone, with the combination therapy being preferred due to lower corticosteroid-related side effects (10% vs 44%) 1, 2
The combination therapy regimen consists of prednisolone 30 mg/day (Week 1) → 20 mg/day (Week 2) → 15 mg/day (Weeks 3-4) → 10 mg/day maintenance, plus azathioprine 50 mg/day throughout 2

The American Gastroenterological Association recommends never using corticosteroids for maintenance therapy in inflammatory bowel disease, as they are effective only for inducing remission, not preventing relapse 4
The European Crohn’s and Colitis Organisation suggests avoiding abrupt discontinuation of corticosteroids after long-term therapy, and screening for osteoporosis risk in patients requiring prolonged or repeated corticosteroid courses 4